Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland
作者机构：Shanghai Institute of HematologyNational Research Center for Translational MedicineState Key Laboratory of Medical GenomicsRuijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai Public Health Clinical CenterFudan UniversityShanghai 200083China Department of Infectious DiseasesResearch Laboratory of Clinical VirologyNational Research Center for Translational MedicineRuijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China State Key Laboratory of Microbial MetabolismSchool of Life Sciences and BiotechnologyThe Joint International Research Laboratory of Metabolic and Developmental SciencesShanghai Jiao Tong UniversityShanghai 200240China
出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)
年 卷 期：2023年第17卷第4期
页 面：758-767页
核心收录：
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
基 金：supported by grants from the National Natural Science Foundation of China(Nos.82100158,81890994,81770143,81970130,and 81861148030) Double First-Class Project(No.WF510162602)from the Ministry of Education State Key Laboratory of Medical Genomics,Overseas Expertise Introduction Project for Discipline Innovation(111 Project,No.B17029) National Key R&D Program of China(Nos.2019YFA0905902 and 2018YFA0107802) Natural Science Foundation of Shanghai(Nos.20JC1410600,21ZR1480900,and 21YF1427900) Shanghai Clinical Research Center for Hematologic Disease(No.19MC1910700) Shanghai Major Project for Clinical Medicine(No.2017ZZ01002) Shanghai Shenkang Hospital Development Center(No.SHDC2020CR5002) Innovative Research Team of High-level Local Universities in Shanghai,Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research(No.2019CXJQ01) Shanghai Jiao Tong University(No.YG2021QN19) Shanghai Guangci Translational Medical Research Development Foundation
主 题：SARS-CoV-2 COVID-19 Omicron genomic epidemiology
摘 要：With the recent ongoing autumn/winter 2022 COVID-19 wave and the adjustment of public health control measures,there have been widespread SARS-CoV-2 infections in Chinese *** we have analyzed 369 viral genomes from recently diagnosed COVID-19 patients in Shanghai,identifying a large number of sublineages of the SARS-CoV-2 Omicron *** analysis,coupled with contact history tracing,revealed simultaneous community transmission of two Omicron sublineages dominating the infections in some areas of China(BA.5.2 mainly in Guangzhou and Shanghai,and BF.7 mainly in Beijing)and two highly infectious sublineages recently imported from abroad(XBB and BQ.1).Publicly available data from August 31 to November 29,2022 indicated an overall severe/critical case rate of 0.035%nationwide,while analysis of 5706 symptomatic patients treated at the Shanghai Public Health Center between September 1 and December 26,2022 showed that 20 cases(0.35%)without comorbidities progressed into severe/critical conditions and 153 cases(2.68%)with COVID-19-exacerbated comorbidities progressed into severe/critical *** observations shall alert healthcare providers to place more resources for the treatment of severe/critical ***,mathematical modeling predicts this autumn/winter wave might pass through major cities in China by the end of the year,whereas some middle and western provinces and rural areas would be hit by the upcoming infection wave in mid-to-late January 2023,and the duration and magnitude of upcoming outbreak could be dramatically enhanced by the extensive travels during the Spring Festival(January 21,2023).Altogether,these preliminary data highlight the needs to allocate resources to early diagnosis and effective treatment of severe cases and the protection of vulnerable population,especially in the rural areas,to ensure the country’s smooth exit from the ongoing pandemic and accelerate socio-economic recovery.
维普期刊数据库
同方期刊数据库